Trial · NCT07890285
A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea
NCT07890285, Not yet recruiting, Janssen Korea, Ltd., Korea
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea. Trials, record NCT07890285. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07890285
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea
- NCT number
- NCT07890285
- Status
- Not yet recruiting
- Enrollment
- 333 participants, estimated
- Lead sponsor
- Janssen Korea, Ltd., Korea
- Conditions
- Pulmonary Arterial Hypertension
- First posted
- 2026-10-22
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Adverse Events (AEs) | Up to 12 months | An AE is any untoward medical occurrence in a patient administered a medicinal product. An AE does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal finding or lack of expected pharmacological action), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product. |
| Primary | Number of Participants With Adverse Drug Reactions (ADRs) | Up to 12 months | An ADR is defined as a response to a medicinal product that is noxious and unintended. The phrase "response to a medicinal product" means that a causal relationship between a medicinal product and an AE is at least a reasonable possibility. |
| Primary | Number of Participants With Serious Adverse Events (SAEs) | Up to 12 months | A SAE is any untoward medical occurrence that at any dose:(a) Results in death; (b) Is life-threatening; (c) Requires inpatient hospitalization or prolongation of existing hospitalization; (d) Results in persistent or significant disability/incapacity; (e) Is a congenital anomaly/birth defect; (f) Is a suspected transmission of any infectious agent via a medicinal product; (g) Is medically important. |
| Primary | Number of Participants With Serious Adverse Drug Reactions (SADRs) | Up to 12 months | Number of participants with SADRs will be reported. |
| Primary | Number of Participants With Unlisted AE, ADR, SAE, and SADR | Up to 12 months | Number of participants with unlisted AE, ADR, SAE, and SADR will be reported. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07890285
GET https://conductscience.org/api/trials/v1/NCT07890285/registered